Barbara PISTILLI
Gustave Roussy Cancer Center · Gustave Roussy, VILLEJUIF · Gustave Roussy, Villejuif, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Barbara PISTILLI as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07294430 · Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.UNICANCER · not yet recruiting · Locally Advanced or Metastatic Breast Cancer · principal investigator
- Ph2NCT07259226 · Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersUNICANCER · recruiting · Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer · principal investigator
- Ph2NCT07192068 · Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.UNICANCER · recruiting · Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer · principal investigator
- Ph2NCT06078384 · Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCUNICANCER · recruiting · Triple-negative Breast Cancer · principal investigator
- Ph3NCT05552001 · Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerUNICANCER · active not recruiting · Triple Negative Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph2NCT04965766 · Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerGustave Roussy, Cancer Campus, Grand Paris · recruiting · Metastatic Breast Cancer, Advanced Breast Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:46 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- 441 citationsRCR 13.0
- Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.Adv Ther · 2013415 citationsRCR 10.2
- Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med · 2023384 citationsRCR 32.5
- 327 citationsRCR 20.7
- 193 citationsRCR 45.2
- 191 citationsRCR 8.1
- Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Breast Cancer Res Treat · 201474 citationsRCR 1.8
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.N Engl J Med · 202674 citationsRCR 37.0
- 57 citationsRCR 2.4
- 55 citationsRCR 1.5